Another visit of the opening of the center was conducted: we study the drugs of the pharmaceutical company Eli Lilly in a randomized, double-blind, placebo-controlled phase II trial with adaptive design in patients with moderate and severe ulcerative colitis.
An initiation visit took place: patients with Crohn's disease will continue to participate in a new multicenter open extended phase 3 study to assess the long-term efficacy and safety of Mirikizumab in patients with Crohn's disease.
We continue to cooperate with the pharmaceutical company Pfizer: participation in a series of clinical trials of new IPs for the treatment of patients with ulcerative colitis has been proposed.
A selection visit was successfully completed to participate in a randomized, double-blind, placebo-controlled 24-week phase 3b study to eliminate moderate and severe vasomotor symptoms (hot flashes) in postmenopausal women for whom hormone replacement therapy is unacceptable.
